Abstract:What's New? Patients with non‐muscle‐invasive bladder cancer (NMIBC) have a high risk of recurrence, and although smoking is considered the most important modifiable risk factor for bladder cancer, it is not clear from the data how smoking affects the risk of recurrence and progression of NMIBC. Here, the authors analyzed data from the prospective, multi‐center UroLife study, which collected data on a variety of factors related to smoking habits. Heavier smoking was associated with higher recurrence risk, especially among patients treated with Bacillus Calmette‐Guerin immunotherapy. However, they found no associations with smoking status, duration, or time since cessation. Studies on the relationship of cigarette smoking with the risks of recurrence and progression of non‐muscle‐invasive bladder cancer (NMIBC) are inconsistent and prospective data are scarce. Therefore, we aimed to assess the association of smoking behavior with risks of NMIBC recurrence and progression. We used data of the prospective multi‐center cohort study UroLife, including 1495 patients with NMIBC who reported information on smoking at 6 weeks post‐diagnosis (baseline; reflecting present and pre‐diagnosis). This included smoking status (also based on reporting 3 months post‐diagnosis), intensity, duration, pack years, and time since smoking cessation, if applicable. Hazard ratios and 95% confidence intervals (CIs) for risks of first recurrence, multiple recurrences, and progression were computed using multivariable proportional hazards regression models. During a total median follow‐up period of 4.6 years, 517 patients developed ≥1 recurrence and 163 had progression. Higher versus lowest categories of smoking intensities and pack years up to baseline were significantly associated with a higher risk of first recurrence. No significant linear associations were found, except for smoking intensity among BCG‐treated patients (per 10 cigarettes/day increase: HR 1.23, 95%CI 1.02, 1.48). No associations for smoking status, duration, and time since cessation were observed. Analyses of multiple recurrence risk showed comparable results. Regarding progression risk, no consistent associations were found. In conclusion, heavier smoking was associated with higher recurrence risk, particularly among BCG‐treated patients. This may be attributable to persistent damage through its carcinogenic compounds. Given the mixed results across different exposures, the effect of smoking behavior on NMIBC prognosis remains unclear.

Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer

Smoking behavior and the risks of tumor recurrence and progression in patients with non‐muscle‐invasive bladder cancer

The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

Advances in relationship between smoking and bladder cancer

From tobacco smoking to mutational signature: the role of epigenetic changes in human cancers

Impact of smoking intensity on outcomes of patients with non muscle invasive bladder cancer treated by BCG immunotherapy

Combined Effects of Cigarette Smoking, Gene Polymorphisms and Methylations of Tumor Suppressor Genes on Non Small Cell Lung Cancer: a Hospital-Based Case-Control Study in China

New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer

The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

RNA-seq analysis of non-muscular invasive bladder cancer to reveal different gene expression profiles between smoking and non-smoking patients.

Interaction of Smoking and Metabolic Syndrome in Increasing the Recurrence Risk of Colorectal Cancer in a Chinese Male Cohort: a Retrospective Study

Exploring the risk factors of recurrence and progression in 188 patients with non-muscle invasive bladder cancer by retrospectively analysis

Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer

Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments.

Can Smoking Cause Differences in Urine Microbiome in Male Patients with Bladder Cancer? A Retrospective Study.

Assessing the predictive value of smoking history for immunotherapy outcomes in bladder cancer patients

Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images

Effect of smoking status on immunotherapy for lung cancer: a systematic review and meta-analysis

Re: Factors Affecting Recurrence and Progression of High Grade Non Invasive Bladder Cancer Treated by Intravesical BCG.

The impact of smoking on survival in renal cell carcinoma: a systematic review and meta-analysis

The effect of cigarette smoking on lung cancer evolution